This week’s Journal Watch discusses a clinical trial from the journal Clinical Endocrinology - “A novel treatment for height growth in patients with growth hormone insensitivity syndrome by cyproheptadine hydrochloride.” Authors: Maryam Razzghy-Azar, Mitra Nourbakhsh, Mona Nourbaksh Highlights Growth hormone insensitivity syndrome (GHIS) is a defect in the GH receptor or post-receptor signals, which results in resistance to GH and causes severe growth retardation. Current treatment with insulin-like growth factor 1 (IGF-1) is unaffordable and associated with several adverse effects.
Cyproheptadine hydrochloride (CyproH), an appetite stimulating drug, has proven to be effective in improving height in GHIS patients. Key takeaways CyproH has a positive effect in promoting growth in patients with GHIS with no adverse effects and therefore can be considered as an alternative option to…
